{"id":"ulimorelin-intravenously-iv","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Abdominal pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Ulimorelin works by mimicking the action of ghrelin, a natural hormone that helps regulate gastric emptying. This leads to faster movement of food from the stomach to the small intestine, which can help alleviate symptoms of gastroparesis.","oneSentence":"Ulimorelin is a ghrelin receptor agonist that stimulates gastric emptying.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:40.025Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Symptomatic gastroesophageal reflux disease (GERD) in patients with type 1 diabetes mellitus"},{"name":"Symptomatic diabetic gastroparesis"}]},"trialDetails":[{"nctId":"NCT01296620","phase":"PHASE3","title":"Ulimorelin Study of Efficacy and Safety (ULISES 008)","status":"COMPLETED","sponsor":"Tranzyme, Inc.","startDate":"2011-02","conditions":"Gastrointestinal Dysmotility","enrollment":330},{"nctId":"NCT01285570","phase":"PHASE3","title":"Ulimorelin Study of Efficacy and Safety (ULISES 007)","status":"COMPLETED","sponsor":"Tranzyme, Inc.","startDate":"2011-01","conditions":"Gastrointestinal Dysmotility","enrollment":332}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ulimorelin Intravenously (IV)","genericName":"Ulimorelin Intravenously (IV)","companyName":"Tranzyme, Inc.","companyId":"tranzyme-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ulimorelin is a small molecule administered intravenously, studied for its efficacy and safety in treating gastrointestinal dysmotility. It is being investigated in a clinical trial, ULISES 008, as a potential treatment for this condition.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}